Boehringer In­gel­heim per­ma­nent­ly shelves pro­duc­tion of cloni­dine, cit­ing ear­li­er re­call and mar­ket com­peti­tors

One less ver­sion of cloni­dine, the decades-old blood pres­sure and AD­HD drug, is now on the shelves.

Boehringer In­gel­heim will dis­con­tin­ue its pro­duc­tion of Cat­apres, telling the FDA the de­ci­sion was due to both an Oc­to­ber re­call and a num­ber of copy­cat drugs al­ready on the mar­ket from oth­er man­u­fac­tur­ers.

BI, the Ger­man phar­ma gi­ant, vol­un­tar­i­ly re­called lots of three dif­fer­ent dos­es of cloni­dine hy­drochlo­ride vari­ant Cat­apres af­ter an ex­tra­ne­ous peak in a dis­so­lu­tion test, the com­pa­ny said at the time.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.